Cytoplasmic immunoglobulin content in multiple myeloma

Cytoplasmic immunoglobulin content in multiple myeloma

Item
http://www.wikidata.org/entity/Q34549519
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisTotal Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapyThe flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains.Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains.Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.Suppression of abnormal karyotype predicts superior survival in multiple myeloma.VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myelomaF18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.Tumor necrosis factor-alpha and interleukin 4 in myeloma cell precursor differentiation.Myeloma cells with asurophilic granules--an unusual morphological variant--case presentationFlow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120).Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.A novel multiparametric approach for analysis of cytoplasmic immunoglobulin light chains by flow cytometry.Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.Malignant pleural effusion of multiple myeloma: prognostic factors and outcome.Primary extranodal non-Hodgkin's lymphoma in adults: clinicopathological and survival characteristics.
P2860

Cytoplasmic immunoglobulin content in multiple myeloma

Item
http://www.wikidata.org/entity/Q34549519
description
1985 nî lūn-bûn
@nan
1985 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Cytoplasmic immunoglobulin content in multiple myeloma
@ast
Cytoplasmic immunoglobulin content in multiple myeloma
@en
Cytoplasmic immunoglobulin content in multiple myeloma
@nl
type
label
Cytoplasmic immunoglobulin content in multiple myeloma
@ast
Cytoplasmic immunoglobulin content in multiple myeloma
@en
Cytoplasmic immunoglobulin content in multiple myeloma
@nl
prefLabel
Cytoplasmic immunoglobulin content in multiple myeloma
@ast
Cytoplasmic immunoglobulin content in multiple myeloma
@en
Cytoplasmic immunoglobulin content in multiple myeloma
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932
P356
P1433
P1476
Cytoplasmic immunoglobulin content in multiple myeloma
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932